## Martin J Edelman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4192343/publications.pdf

Version: 2024-02-01

22 papers 854 citations

758635 12 h-index 18 g-index

24 all docs

24 docs citations

times ranked

24

1444 citing authors

#	Article	IF	CITATIONS
1	Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer. JAMA Oncology, 2018, 4, 1263.	3.4	273
2	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	0.6	210
3	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678.	1.3	145
4	Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. Journal of Thoracic Oncology, 2020, 15, 1137-1146.	0.5	31
5	Daily diary study of hope, stigma, and functioning in lung cancer patients Health Psychology, 2018, 37, 218-227.	1.3	28
6	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 361-375.	0.4	22
7	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 <sup>+</sup> advanced non-small cell lung cancer., 2022, 10, e003581.		19
8	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). Oncogenesis, 2021, 10, 29.	2.1	18
9	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. Journal of Thoracic Oncology, 2021, 16, 66-75.	0.5	17
10	Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 445-452.	0.4	16
11	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limitedâ€stage small cell lung cancer in elderly patients versus younger patients. Cancer, 2019, 125, 382-390.	2.0	14
12	Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non–small-cell Lung Cancer at Diagnosis. Clinical Lung Cancer, 2019, 20, e107-e114.	1.1	14
13	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 54-65.	0.5	13
14	Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non–small-cell Lung Cancer Treated With Curative Intent. Clinical Lung Cancer, 2020, 21, e130-e141.	1.1	8
15	Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients. Supportive Care in Cancer, 2020, 28, 827-835.	1.0	7
16	Clinical outcomes of black vs. non-black patients with locally advanced non–small cell lung cancer. Lung Cancer, 2017, 114, 44-49.	0.9	6
17	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	3.4	6
18	The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review. International Journal of Radiation Oncology Biology Physics, 2020, 108, 38-45.	0.4	5

#	Article	IF	CITATIONS
19	Biomarker Testing in Lung Cancer—What Does It Mean?. JAMA Network Open, 2020, 3, e207171.	2.8	1
20	Benchmarks for Academic Oncology Faculty. JCO Oncology Practice, 2021, 17, e440-e444.	1.4	1
21	Population-Based Outcomes in NSCLC. JNCI Cancer Spectrum, 2019, 3, pkz022.	1.4	O
22	Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , .	2.3	0